Gestational trophoblastic neoplasia: does centralization of care impact clinical management?


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
06 11 2023
Historique:
medline: 8 11 2023
pubmed: 19 9 2023
entrez: 18 9 2023
Statut: epublish

Résumé

International societies advocate for gestational trophoblastic neoplasia referral to designated expert centers. This study assessed the impact of centralization of trophoblastic care on clinical outcomes. A centralized program was implemented in 2018 at two affiliated academic hospitals, Princess Margaret Cancer Center and Mount Sinai Hospital. A retrospective analysis of patients treated between 2000 and 2022 was performed and the clinical outcomes were compared before (2000-2017) and after (2018-2022) centralization. Statistical analyses were performed with significance set as p<0.05. A total of 94 patients with trophoblastic neoplasia were included: 60 pre-centralization and 34 post-centralization, 79.8% low-risk and 18.1% high-risk. Centralization led to significant improvement for: (1) accurate score documentation (from 37.9% to 89.3%,); (2) contraception counseling (from 67.2% to 96.7%); (3) median time from diagnosis to chemotherapy (from 9 days to 1 day); and (4) incomplete follow-up (from 20.7% to 3.3%) (all p<0.05). First-line chemotherapy for low-risk neoplasia was dactinomycin in 47.9% and 87.0% pre- and post-centralization, respectively (p=0.005). The median number of chemotherapy cycles decreased from seven to four (p=0.01), and the median number of consolidation cycles increased from two to three (p<0.001). Serum human chorionic gonadotropin (hCG) levels of 10 000-100 000 IU/L were significantly associated with longer time to hCG normalization and higher risk of resistance to first-line chemotherapy compared with hCG levels <1000 IU/L. Centralization of trophoblastic neoplasia care leads to greater guideline compliance, faster chemotherapy initiation, fewer chemotherapy cycles with optimized consolidation, and enhanced surveillance completion. This supports the establishment of trophoblastic neoplasia expert centers.

Identifiants

pubmed: 37723102
pii: ijgc-2023-004526
doi: 10.1136/ijgc-2023-004526
doi:

Substances chimiques

Chorionic Gonadotropin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1724-1732

Informations de copyright

© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Cristina Mitric (C)

Sinai Health, Toronto, Ontario, Canada cristina.mitric@gmail.com.
Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada.
Princess Margaret Cancer Centre/ University Health Network, Toronto, Ontario, Canada.

Kelsey Yang (K)

Sinai Health, Toronto, Ontario, Canada.
Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada.
Princess Margaret Cancer Centre/ University Health Network, Toronto, Ontario, Canada.

Gita Bhat (G)

Medical Oncology, Princess Margaret Cancer Centre/ University Health Network, Toronto, Ontario, Canada.

Stephanie Lheureux (S)

Medical Oncology, Princess Margaret Cancer Centre/ University Health Network, Toronto, Ontario, Canada.

Stephane Laframboise (S)

Sinai Health, Toronto, Ontario, Canada.
Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada.
Princess Margaret Cancer Centre/ University Health Network, Toronto, Ontario, Canada.

Xuan Li (X)

Department of Biostatistics, Princess Margaret Cancer Centre/ University Health Network, Toronto, Ontario, Canada.

Geneviève Bouchard-Fortier (G)

Sinai Health, Toronto, Ontario, Canada.
Department of Obstetrics and Gynaecology, University of Toronto, Toronto, Ontario, Canada.
Princess Margaret Cancer Centre/ University Health Network, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH